NCT01975688 - A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

June 30, 2015

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

Sativex

"Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.~Each vial contains 10 mL; each 100 uL actuation delivers 2.7 mg THC and 2.5 mg CBD."

Trial Locations (1)

SE1 1YR

Quintiles London Drug Research Unit, London